Compare PII & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PII | PBLS |
|---|---|---|
| Founded | 1954 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.6B |
| IPO Year | 1994 | 2026 |
| Metric | PII | PBLS |
|---|---|---|
| Price | $52.35 | $31.46 |
| Analyst Decision | Hold | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $62.27 | N/A |
| AVG Volume (30 Days) | ★ 715.6K | 707.2K |
| Earning Date | 04-27-2026 | N/A |
| Dividend Yield | ★ 4.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,152,000,000.00 | N/A |
| Revenue This Year | $1.20 | N/A |
| Revenue Next Year | $4.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $47.14 | $25.56 |
| 52 Week High | $77.98 | $42.49 |
| Indicator | PII | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 27.71 | 37.75 |
| Support Level | $52.22 | $26.42 |
| Resistance Level | $74.00 | $33.65 |
| Average True Range (ATR) | 1.94 | 3.26 |
| MACD | -0.14 | -0.93 |
| Stochastic Oscillator | 9.32 | 14.63 |
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational, utility, military, and commercial purposes, snowmobiles, and on-road vehicles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to pontoon and deck boat users. It is slated to divest its Indian motorcycle brand to Carolwood in the first quarter of 2026. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.